GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose
NCT ID: NCT01079624
Last Updated: 2010-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
15 participants
INTERVENTIONAL
2006-08-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Separate and Combined Extrapancreatic Effects of GIP and GLP-1
NCT06895408
Separate and Combined Extrapancreatic Effects of the Incretin Hormones
NCT05177653
Physiology of GIP(1-30)NH2 in Humans
NCT04792762
Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism
NCT00999271
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
NCT06194955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GIP two doses and GLP-1 one dose
Intervention with infusion of GIP or GLP-1 intravenously
Glucose-insulinotropic peptide, Glucagon-like peptide-1
GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
Saline infusion
Control
Glucose-insulinotropic peptide, Glucagon-like peptide-1
GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glucose-insulinotropic peptide, Glucagon-like peptide-1
GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-50 years old;
* otherwise healthy and HIV and HCB, HCV negative
Exclusion Criteria
* all types of diseases and drug users.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
University of Copenhagen
OTHER
Uppsala University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Uppsala University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Per M Hellstrom, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet, Uppsala University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska University Hospital
Stockholm, Stockholm County, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
K2010-55X -07916-24-3
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
GIP/GLP-gastric empt-APP-hor
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.